Aussie Health Chief Vows To End Delay In Doctor PBS Prescriptions
This article was originally published in PharmAsia News
Australia's health minister says the government is taking steps to ease some of the delays in physician ability to prescribe covered drugs
You may also be interested in...
PERTH, Australia - Oncology drug prices in Australia were roughly 30 percent lower than in the U.S. over the past decade, thanks to comparative effectiveness policies imposed by Australia's Pharmaceutical Benefits Scheme, according to a recent study conducted by the Tufts Center for the Study of Drug Development
The evidence-based approach adopted by Australia has led to lower prices, improving the affordability of those medications considered cost-effective for payers and patients by the reimbursement authority, the report says.
Pink Sheet Podcast: Adcomm Rejects NurOwn For ALS, FDA In Shutdown Mode, Limited Price Negotiation Savings
Pink Sheet reporters and editors consider the fallout from Brainstorm Cell Therapeutics Inc.’s negative US FDA advisory committee decision on its ALS drug, the impact of a government shutdown on the agency, and a study showing only a limited possibility for significant savings in the first round of Medicare price negotiations.